Stock info Qiagen | Filter  Basic-Info

Qiagen

The company mostly operates in the biotech sector. The global biotech companies gained around 59 percent worldwide over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Past year was a negative year for Qiagen investors

Over the last 12 months, that were profitable period for the investors in Qiagen , the stock gained around 7 percent. Qiagen ' stock rose the past 5 years at around 161 percent. Qiagen 's revenues between 2011 and 2015 were relatively steady and moved between 1,02 billion euros and 1,15 billion euros. Qiagen 's net results between 2011 and 2015 were far from constant and moved between 71,93 million euros and 114,6 million euros.

The German company didn't pay out any dividends (in the past 5 years).

The German company had ultimo 2015 approximately 3800 thousand employees on it's payroll.

Qiagen ' balance mostly financed with equity

At the end of 2015 the German company's balance sheet was worth 3,86 billion euros. 1,5 billion euros (38,9 percent of the total balance sheet) was financed by debt. At the end of 2015 the biotech company's stock was traded with a price/earnings-ratio 40. So the stock' value was 40 times the 2015' earnings per share. Many analysts say that based on her price/earnings-ratio and dividend yield the German stock can be seen as a growth stock.

At the end of 2015 the biotech company's market capitalization (the number of shares times the market price) equaled around 5,96 billion euros. At the end of 2015 the German company had around 241,54 million stocks listed.

All Qiagen 's annual reports can be found here. More information about Qiagen can be found it's website. .